November 9, 2021- ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series- OnDemand- Molecular biomarkers for response to immunotherapy in endometrial cancer-November 9, 2021- ClinGen Somatic Cancer and VICC

Video Transcription

Video Summary

In this video, Drs. Ian King, Nicole Park, and Eduardo González present their project on molecular biomarkers for response to immunotherapy in endometrial cancer. They discuss the classification of endometrial cancer based on molecular subgroups and its importance for prognosis and response to immunotherapy. The first case presented is a patient with grade 2 endometrial cancer and mismatched repair deficiency, who showed a good response to immunotherapy. This case highlights the relevance of tumor mutation burden and Poly D1 variants as biomarkers for predicting response to immunotherapy. The second case is a patient with advanced endometrial cancer and clear cell histology, who also had a good response to immunotherapy. The third case is a patient who initially showed mixed response to immunotherapy but later stabilized. This case demonstrates the complexity of biomarkers and the need for further research in this field. The speakers discuss the potential of neoantigen prediction and the evaluation of the tumor and immune microenvironment as additional biomarkers. They also mention the importance of circulating tumor DNA for monitoring treatment response. They conclude by highlighting the need for multiple biomarkers and the practical considerations for biomarker testing. Ultimately, the goal is to improve the prediction of response to immunotherapy and guide treatment decisions for patients with endometrial cancer.

Keywords

molecular biomarkers

response to immunotherapy

endometrial cancer

molecular subgroups

prognosis

tumor mutation burden

Poly D1 variants

tumor microenvironment

circulating tumor DNA

biomarker testing